There are papers suggesting that imatinib is a broad-based kinase inhibitor and far less selective than second generation TKIs. The thought is imatinib is acting as a cretatine kinase inhibitor. This appears to be underesearched.
a little appears here: https://www.medscape.com/viewarticle/834956